People in the News

May 08, 2018

Michael Stocum

Michael Stocum has stepped down as CEO of Inivata "to pursue other interests," according to the company. Inivata said it has initiated a search for a new CEO.

May 08, 2018

Terry Pizzie

Horizon Discovery Group has appointed Terry Pizzie as CEO and board member, effective immediately. Pizzie joined Horizon in 2017 as head of commercial operations and has nearly 30 years of experience in the biotechnology tools sector. Prior to joining Horizon, Pizzie worked for Pacific Biosciences, first as a vice president in Europe, and later as head of global sales. His previous leadership roles include director of global commercial operations at Genetix prior to its acquisition by Danaher, and senior vice president of global commercial operations at Swedish biotech firm Biacore. He started his career at Applied Biosystems in 1988.

May 04, 2018

Berndt Modig

Centogene announced today that it has appointed Berndt Modig to its supervisory board. Modig currently serves as director and audit committe chair of Axovant Sciences, member of the audit committee of Affimend, and vice chairman of the supervisory board and chair of the audit committee at Kiadis Pharma. In addition, Modig is currently CEO and co-founder of Pharvaris.

Modig previously served as CFO of Prosensa Hodling from Mar. 2010 until its 2015 acquisiotn by BioMarin Pharmaceutical. Prior to Prosensa holding, Modig was CFO at Jerini AG. Modig has also held a variety of senior management positions at Surplex AG, Hayward Industrial Products, Agra Industrial, and Price Waterhouse. 

May 04, 2018

Charles Bodner

Becton Dickinson has elected Charles Bodner to the role of senior vice president of corporate finance and chief accounting officer. Effective July 1, 2018, Bodner will replace John Gallagher, who will transition to another senior role at BD. Bodner has been BD's senior vice president and CFO of the firm's medical segment since 2013, and CFO of the international business segment since 2017.

May 04, 2018

Alberto Mas, Patrick Kaltenbach, Bill Tozzi

Becton Dickinson has announced three executive leadership changes. Alberto Mas will now lead the firm's medical segment; Patrick Kaltenbach will head up life sciences, replacing Mas, effective May 29; and Bill Tozzi will lead the firm's interventional segment on an interim basis.

Mas was head of BD's life sciences business for two years, and previously served as president of three of the firm's other major business units. Kaltenbach previously served as senior vice president of life sciences and applied markets at Agilent. Tozzi had been serving as the integration leader for the CR Bard transaction since April 2017, and prior to that was the president of the firm's medication delivery solutions division for six years. Tozzi will replace John Groetelaars, who served as the president of the interventional segment since the completion of the Bard transaction and who has decided to leave BD for an executive position at another company.

Mas was head of Life Sciences for two years, and previously served as president of three of the firms other major business units. 

Kaltenbach will replace Mas effective May 29, 2018. He previously served as senior vice president of life sciences and applied markets at Agilent, a position he held since 2014.

Tozzi had been serving as the integration leader for the CR Bard transaction since April 2017, and prior to that was the president of the firm's medication delivery solutions division for six years. Tozzi will replace John Groetelaars, who served as the president of the interventional segment since the completion of the Bard transaction and who has decided to leave BD for an executive position at another company.

May 01, 2018

John Roberts

Cancer Genetics has appointed John Roberts as CEO and president. Roberts had been serving as interim CEO since February, in addition to serving as chief operating officer and executive VP of finance, positions he has held since July 2016. Roberts served as CFO for VirMedica from August 2015 to June 2016. Prior to VirMedica, Roberts served as chief financial and administrative officer for AdvantEdge Healthcare Solutions, CFO and treasurer for InfoLogix, and as CFO at public medical device and healthcare firms including Clarient and Daou Systems.

Apr 30, 2018

Maneesh Arora

Exact Sciences Chief Operating Officer Maneesh Arora will be leaving the company at the end of the year. During a conference call with analysts following the release of the company's first quarter earnings, Exact CEO Kevin Conroy announced that Arora "will transition to a life outside of Exact Sciences," adding that he will spend the rest of 2018 "focusing his operational and strategic rigor on the priority of advancing our pipeline plans to fuel our future success." The company does not anticipate finding a replacement COO at this time, Conroy noted.

Apr 30, 2018

Holger Reithinger

Holger Reithinger has resigned from Curetis' supervisory board effective April 30. He had been on the board since the company went public in 2015. Reithinger is a general partner at venture capital firm Forbion. Curetis' board now has six members. His replacement has not been named, and the company is "exploring options ... to further evolve" its board composition, Curetis said. 

Apr 25, 2018

Jacob Thaysen and Sam Raha

Agilent Technologies has appointed Jacob Thaysen president of the firm's life sciences and applied markets group, replacing Patrick Kaltenbach, who left the company on April 20. Thaysen currently serves as a senior vice president at the company and as president of its diagnostics and genomics group. He joined Agilent in 2012 as part of the acquisition of Dako, where he served as corporate vice president of R&D. Before that, Thaysen was founding partner and chief technology officer of Cantion, a research and defense application development company based in Denmark.

Agilent also announced that Sam Raha, who currently serves as senior vice president of the firm's strategy and corporate development group, will take over as president of the diagnostics and genomics group. Raha previously served as vice president of global marketing at Illumina, and vice president and general manager of the genomic assays business unit at Life Technologies. He also held the position of vice president and general manager of Agilent's Americas field operations for the life sciences and chemical analysis group from 2004 to 2007.

Thaysen's and Raha's appointments are effective immediately, and both will continue to report to Agilent President and CEO Mike McMullen, the firm said.

Apr 24, 2018

Kim Kelderman

Bio-Techne has hired Kim Kelderman as president of Diagnostics and Genomics, effective April 30. Based in California, Kelderman will lead Bio-Techne's diagnostics business, and drive and develop the company's initiatives in genomics and genomics-based diagnostics. He joins Bio-Techne from Thermo Fisher Scientific, where for the past three years he managed the platforms and content of the Genetic Sciences Division. In that position he was responsible for the instrumentation, software, consumables, and assays businesses, and brands including Applied Biosystems and legacy Affymetrix. Prior to being at Thermo Fisher, he was a segment leader at Becton Dickinson. 

Apr 24, 2018

Heiner Dreismann

Heiner Dreismann, former CEO of Roche Molecular Systems, has joined the executive advisory board of MyDx, maker of a multi-use handheld chemical analyzer designed for cannabis professionals and retail consumers. Under Dreismann's leadership, Roche expanded its portfolio of molecular tests and instruments. Prior to his appointment as CEO of Roche Molecular, Dreismann held other senior positions within Roche, including as head of global business development for Roche Diagnostics, European business unit manager for PCR, head of its business unit for microbiology, R&D positions in microbiology and infectious diseases, and head of manufacturing for infectious disease diagnostics.

Apr 24, 2018

Kenneth Berlin

Former Rosetta Genomics CEO Kenneth Berlin has been appointed president and CEO of Advaxis, effective April 23. Berlin had been president and CEO of Rosetta since 2009 before he stepped down on April 18. That firm and Genoptix have been trying to reach a deal for Genoptix's purchase of the company. Berlin previously has held executive positions at Johnson & Johnson, and J&J firms Veridex and Ortho-Clinical Diagnostics. 

Apr 23, 2018

Brad Kreger

Brad Kreger has been named senior VP of global operations at Fluidigm. Prior to joining the company, he served as senior director of manufacturing operations in Thermo Fisher Scientific's clinical next-generation sequencing division. Before that, he worked for Affymetrix for two decades, most recently as VP of reagent manufacturing and global process engineering.

Apr 20, 2018

Margo Georgiadis

Ancestry announced today that it has appointed Margo Georgiadis as CEO and member of its board of directors. Georgiadis will join the company on May 10. She will succeed Howard Hochhauser, who served as interim CEO since Oct 2017. Hochhauser will return to his position as Ancestry's CFO and COO. Georgiadis previously served as CEO at Mattel, and prior to that as President, Americas at Google.

Apr 20, 2018

William Bonello

NeoGenomics has appointed William Bonello VP of strategy, corporate development and investor relations. Bonello has served as the company's VP, treasurer, and director of corporate development since April of last year. Previously Bonello worked as a healthcare equity analyst covering diagnostic services and product stocks for Craig-Hallum, and as an equity analyst for Piper Jaffray, Wachovia Securities, and RBC Capital Markets. Bonello was also previously senior VP for investor relations at Laboratory Corporation of America.

Apr 17, 2018

Patrick Kaltenbach

Agilent said that Patrick Kaltenbach, senior VP for the company and president of Agilent's Life Sciences and Analytical Group, will leave the company on April 20. The company did not provide a reason for Kaltenbach's departure. The search for a replacement for his position is underway, Agilent said.

Apr 16, 2018

John Lubniewski

John Lubniewski has been promoted by HTG Molecular Diagnostics to president and chief operating officer. Lubniewski has been the company's chief business officer for the past seven years. He joined HTG from Ventana, now part of Roche, where he held several senior leadership roles, and was responsible for marketing and global accountability for all assay products. Prior to joining Ventana, he was with Corning.

Apr 16, 2018

Richard Williams

Richard Williams has become managing director and head of oncology programs at WuXi Nextcode. He joins the company from Grail, where he was lead medical director of the Circulating Cell-Free Genome Atlas program. Prior to that, he held positions in oncology drug development at Amgen and at Puma Technology. Williams holds B.Med.Sc and PhD degrees, as well as bachelor of medicine and bachelor of surgery degrees, from the University of Queensland in Australia.

Apr 13, 2018

Aleksandar Rajkovic

Aleksandar Rajkovic has become the first chief genomics officer of the University of California, San Francisco. He joins UCSF from the University of Pittsburgh Medical Center, where he was division director of reproductive genetics. In his new role, Rajkovic will direct the activities of UCSF's existing clinical genomics laboratories, in addition to leading efforts to apply genetics and genomics to clinical care within the health system.

Apr 13, 2018

Irwin Jacobs, Martin Wygod

Biological Dynamics has added Irwin Jacobs and Martin Wygod to its board of directors. Jacobs is a cofounder of semiconductor and telecommunications equipment firm Qualcomm, as well as chairman emeritus of the Salk Institute for Biological Studies. Wygod is director of Medco Containment Services and former chairman of WebMD Health. 

Apr 13, 2018

Debra Goff, Donna Mildvan, Melissa Miller, Frederick Nolte, Robin Patel

Curetis has established a US scientific advisory board consisting of five infectious disease experts. Debra Goff, Donna Mildvan, Melissa Miller, Frederick Nolte, and Robin Patel will support the clinical adoption of the firm's Unyvero System and lower respiratory tract infection assay recently cleared by the US Food and Drug Administration. 

Goff is currently an infectious diseases specialist with the One Health Antibiotic Stewardship team at The Ohio State University; Mildvan is professor of medicine at Icahn School of Medicine at Mount Sinai in New York; Miller is director of the clinical molecular microbiology laboratory at the University of North Carolina at Chapel Hill School of Medicine; Nolte is medical director of clinical labs and molecular pathology at the Medical University of South Carolina; and Patel is co-director of the clinical bacteriology laboratory, director of the infectious diseases research lab, and chair of the division of clinical microbiology at Mayo Clinic.

Apr 13, 2018

Heidi Rehm

Heidi Rehm last month became chief genomics officer in the Department of Medicine at Massachusetts General Hospital, where she is part of the Center for Genomic Medicine. In her new role, she will focus on the clinical implementation of genomics. Rehm remains medical director of the Broad Institute’s clinical research sequencing platform and an associate professor of pathology at MGH, Brigham and Women’s Hospital, and Harvard Medical School. She is also a leader and principal investigator of ClinGen, and a co-leader of the Broad Center for Mendelian Genomics. Previously, Rehm was the director of the Laboratory for Molecular Medicine at Partners Healthcare Personalized Medicine.

Apr 13, 2018

Michael Murray

Michael Murray has become director for clinical operations in the Center for Genomic Health at Yale University School of Medicine. He joins Yale from the Geisinger Health System, where he was director of clinical genomics and was leading the GenomeFIRST return of results program, which is part of Geisinger’s MyCode Community Heath Initiative. In his new role at Yale, he will similarly focus on bringing clinical genomics to large patient cohorts.

Apr 12, 2018

Richard Kivel

BC Platforms announced today that it has appointed Richard Kivel as company chairman. Kivel is currently managing director at Graybella Captial and holds various director positions in the US and Europe.

Apr 11, 2018

Chris Callahan

PieranDx has named Chris Callahan chief commercial officer, where he will head sales, marketing, and business development efforts. Callahan joins the bioinformatics startup after serving as vice president for product strategy and business development for Sunquest Information Systems. He previously held a managerial-level position at health IT giant Cerner. St. Louis-based PieranDX is in growth mode, having raised $3 million in new funding in February and entered into a partnership with Cancer Genetics last month.

Pages

Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.

CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.

The New York Times reports on a project to develop a tree DNA database to uncover instances of illegal logging.

In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.